The value of interventional mitral valve repair in patients with ischemic or functional mitral valve regurgitation

摘要

Transcatheter mitral valve repair strategies have recently been introduced into clinical practice for treatment of patients with severe mitral regurgitation (MR) and at prohibitively high surgical risk. The MitraClip device for leaflet repair is the only device with experience reported in relevant patient numbers. In the multicenter U.S. EVEREST trial, patients eligible for surgery were randomized to receive either surgical mitral valve repair (MVR) or MitraClip treatment (1). As a result, the majority of patients had degenerative MR while in the European experience most patients treated with the clip have a functional or mixed etiology of MR and are usually at high-risk for surgery (2). Here we sought to assess the value of an interventional mitral valve program using the MitraClip for treatment of patients with predominantly functional MR as an adjunct to surgery.